TABLE 3. V-safe enrollees who completed at least one survey and reported a local or systemic reaction or health impact on days 0–7 after receiving Janssen COVID-19 vaccine — United States, March 2–April 12, 2021.
| Event | Percentage of enrollees reporting reaction or health
impact |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Days 0–7* | Day 0 | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | |
|
Total
enrollees,
no. (%) of enrollees
reporting†
|
338,765 (100)
|
207,483 (61)
|
259,535 (77)
|
261,096 (77)
|
251,676 (74)
|
238,946 (71)
|
225,427 (67)
|
209,958 (62)
|
202,138 (60)
|
|
Reaction
reported
| |||||||||
| Fatigue |
59.1 |
17.9 |
56.3 |
26.2 |
16.7 |
12.8 |
11.0 |
9.8 |
9.0 |
| Injection site pain |
57.9 |
31.6 |
48.5 |
39.1 |
30.1 |
21.5 |
13.7 |
7.9 |
5.0 |
| Headache |
52.2 |
13.0 |
50.8 |
19.9 |
10.8 |
8.1 |
7.6 |
7.5 |
7.4 |
| Myalgia |
47.8 |
9.0 |
47.9 |
19.2 |
9.7 |
6.6 |
5.3 |
4.6 |
4.4 |
| Fever |
34.7 |
4.8 |
37.0 |
8.3 |
2.8 |
1.8 |
1.4 |
1.2 |
1.2 |
| Chills |
34.2 |
5.5 |
35.7 |
6.7 |
2.3 |
1.4 |
1.2 |
1.0 |
1.0 |
| Joint pain |
26.1 |
3.5 |
25.3 |
8.9 |
4.5 |
3.3 |
2.8 |
2.6 |
2.4 |
| Nausea |
18.7 |
3.8 |
15.7 |
5.4 |
3.5 |
2.6 |
2.1 |
1.9 |
1.7 |
| Diarrhea |
9.4 |
0.9 |
4.3 |
3.4 |
2.7 |
2.1 |
1.7 |
1.5 |
1.5 |
| Swelling |
9.3 |
1.8 |
4.6 |
4.6 |
4.4 |
3.9 |
2.9 |
2.1 |
1.5 |
| Abdominal pain |
7.4 |
0.9 |
5.0 |
2.2 |
1.6 |
1.3 |
1.2 |
1.1 |
1.1 |
| Redness |
7.4 |
1.2 |
2.5 |
4.0 |
4.1 |
3.4 |
2.4 |
1.6 |
1.0 |
| Itching |
7.1 |
1.2 |
1.8 |
2.6 |
3.2 |
3.0 |
2.5 |
1.8 |
1.4 |
| Vomiting |
2.1 |
0.2 |
1.6 |
0.4 |
0.2 |
0.2 |
0.2 |
0.2 |
0.2 |
| Rash |
1.9 |
0.2 |
0.5 |
0.6 |
0.6 |
0.6 |
0.6 |
0.6 |
0.6 |
|
Any injection site
reaction§
|
60.7 |
33.1 |
50.3 |
41.8 |
33.1 |
24.1 |
15.9 |
9.7 |
6.6 |
|
Any systemic
reaction¶
|
76.4 |
29.8 |
74.8 |
44.1 |
28.9 |
22.3 |
19.7 |
18.2 |
17.3 |
|
Any health
impact**
|
33.9 |
4.8 |
33.2 |
9.7 |
5.1 |
3.8 |
3.3 |
3.1 |
3.1 |
| Unable to perform normal daily
activities |
28.3 |
3.8 |
27.7 |
7.4 |
4.0 |
3.0 |
2.6 |
2.5 |
2.5 |
| Unable to work |
17.0 |
1.8 |
16.3 |
4.5 |
2.0 |
1.3 |
1.0 |
1.0 |
0.9 |
| Needed medical care |
1.4 |
0.1 |
0.4 |
0.2 |
0.3 |
0.3 |
0.3 |
0.4 |
0.4 |
| Telehealth |
0.53 |
0.02 |
0.16 |
0.09 |
0.11 |
0.12 |
0.11 |
0.12 |
0.12 |
| Clinic |
0.40 |
0.03 |
0.05 |
0.05 |
0.07 |
0.10 |
0.11 |
0.12 |
0.12 |
| Emergency visit |
0.31 |
0.04 |
0.08 |
0.05 |
0.06 |
0.06 |
0.07 |
0.07 |
0.06 |
| Hospitalization | 0.04 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
* Proportion of enrollees who reported a reaction or health impact at least once during postvaccination days 0–7.
† Enrollees were able to respond on multiple days.
§ Injection site pain, swelling, redness, or itching.
¶ Fatigue, headache, myalgia, fever, chills, nausea, diarrhea, abdominal pain, vomiting, or rash at injection site.
** A health impact was defined as being unable to perform normal daily activities, being unable to work, or receiving medical care.